dc.contributor.author | Varhaug, Kristin Nielsen | en_US |
dc.contributor.author | Barro, Christian | en_US |
dc.contributor.author | Bjørnevik, Kjetil Lauvland | en_US |
dc.contributor.author | Myhr, Kjell-Morten | en_US |
dc.contributor.author | Torkildsen, Øivind | en_US |
dc.contributor.author | Wergeland, Stig | en_US |
dc.contributor.author | Bindoff, Laurence | en_US |
dc.contributor.author | Kuhle, Jens | en_US |
dc.contributor.author | Vedeler, Christian A. | en_US |
dc.date.accessioned | 2018-08-28T09:15:49Z | |
dc.date.available | 2018-08-28T09:15:49Z | |
dc.date.issued | 2018 | |
dc.Published | Varhaug K, Barro, Bjørnevik KL, Myhr KM, Torkildsen Ø, Wergeland S, Bindoff L, Kuhle J, Vedeler CA. Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurology: Neuroimmunology and neuroinflammation. 2018;5:e422 | eng |
dc.identifier.issn | 2332-7812 | |
dc.identifier.uri | https://hdl.handle.net/1956/18285 | |
dc.description.abstract | Objective: To investigate whether serum neurofilament light chain (NF-L) and chitinase 3-like 1 (CHI3L1) predict disease activity in relapsing-remitting MS (RRMS). Methods: A cohort of 85 patients with RRMS were followed for 2 years (6 months without disease-modifying treatment and 18 months with interferon-beta 1a [IFNB-1a]). Expanded Disability Status Scale was scored at baseline and every 6 months thereafter. MRI was performed at baseline and monthly for 9 months and then at months 12 and 24. Serum samples were collected at baseline and months 3, 6, 12, and 24. We analyzed the serum levels of NF-L using a single-molecule array assay and CHI3L1 by ELISA and estimated the association with clinical and MRI disease activity using mixed-effects models. Results: NF-L levels were significantly higher in patients with new T1 gadolinium-enhancing lesions (37.3 pg/mL, interquartile range [IQR] 25.9–52.4) and new T2 lesions (37.3 pg/mL, IQR 25.1–48.5) compared with those without (28.0 pg/mL, IQR 21.9–36.4, β = 1.258, p < 0.001 and 27.7 pg/mL, IQR 21.8–35.1, β = 1.251, p < 0.001, respectively). NF-L levels were associated with the presence of T1 gadolinium-enhanced lesions up to 2 months before (p < 0.001) and 1 month after (p = 0.009) the time of biomarker measurement. NF-L levels fell after initiation of IFNB-1a treatment (p < 0.001). Changes in CHI3L1 were not associated with clinical or MRI disease activity or interferon-beta 1a treatment. Conclusion: Serum NF-L could be a promising biomarker for subclinical MRI activity and treatment response in RRMS. In clinically stable patients, serum NF-L may offer an alternative to MRI monitoring for subclinical disease activity. | en_US |
dc.language.iso | eng | eng |
dc.publisher | Wolters Kluwer | eng |
dc.rights | Attribution CC BY-NC-ND | eng |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | eng |
dc.title | Neurofilament light chain predicts disease activity in relapsing-remitting MS | en_US |
dc.type | Peer reviewed | |
dc.type | Journal article | |
dc.date.updated | 2018-03-07T10:58:21Z | |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2017 The Author(s) | |
dc.identifier.doi | https://doi.org/10.1212/nxi.0000000000000422 | |
dc.identifier.cristin | 1562882 | |
dc.source.journal | Neurology: Neuroimmunology and neuroinflammation | |